Mason Carrico
Stock Analyst at Stephens & Co.
(2.06)
# 2,993
Out of 4,996 analysts
74
Total ratings
37.88%
Success rate
-3%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HOLX Hologic | Reiterates: Overweight | $78 | $67.21 | +16.05% | 5 | Sep 18, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $6.5 → $11 | $7.93 | +38.71% | 2 | Sep 2, 2025 | |
| NTRA Natera | Reiterates: Overweight | $183 | $162.97 | +12.29% | 5 | Aug 15, 2025 | |
| VCEL Vericel | Reiterates: Overweight | $67 | $30.23 | +121.63% | 3 | Jun 16, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $105 | $91.69 | +14.52% | 8 | May 20, 2025 | |
| PACB Pacific Biosciences of California | Reiterates: Overweight | $1.8 | $1.21 | +48.76% | 5 | May 15, 2025 | |
| TXG 10x Genomics | Reiterates: Overweight | $14 | $11.72 | +19.45% | 6 | May 15, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $14.94 | +167.74% | 10 | May 5, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $140 → $115 | $79.92 | +43.89% | 1 | May 2, 2025 | |
| VCYT Veracyte | Reiterates: Overweight | $45 | $33.44 | +34.57% | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $55 | $60.03 | -8.38% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $3.40 | +76.47% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $26.80 | -36.57% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $52 | $39.11 | +32.96% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $7.70 | +159.74% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $22.71 | +80.54% | 7 | Jan 2, 2025 |
Hologic
Sep 18, 2025
Reiterates: Overweight
Price Target: $78
Current: $67.21
Upside: +16.05%
NeoGenomics
Sep 2, 2025
Maintains: Overweight
Price Target: $6.5 → $11
Current: $7.93
Upside: +38.71%
Natera
Aug 15, 2025
Reiterates: Overweight
Price Target: $183
Current: $162.97
Upside: +12.29%
Vericel
Jun 16, 2025
Reiterates: Overweight
Price Target: $67
Current: $30.23
Upside: +121.63%
Illumina
May 20, 2025
Reiterates: Overweight
Price Target: $105
Current: $91.69
Upside: +14.52%
Pacific Biosciences of California
May 15, 2025
Reiterates: Overweight
Price Target: $1.8
Current: $1.21
Upside: +48.76%
10x Genomics
May 15, 2025
Reiterates: Overweight
Price Target: $14
Current: $11.72
Upside: +19.45%
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $14.94
Upside: +167.74%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $79.92
Upside: +43.89%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $33.44
Upside: +34.57%
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $60.03
Upside: -8.38%
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $3.40
Upside: +76.47%
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $26.80
Upside: -36.57%
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $39.11
Upside: +32.96%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $7.70
Upside: +159.74%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $22.71
Upside: +80.54%